Table 2. Comparison of minimum inhibitory concentration for ceftazidime/avibactam vs ceftolozane/tazobactam against 109 clinical extended-spectrum -lactamase-producing Enterobacterales isolates from samples from intensive care unit patients at Hamad Medical Corporation, Qatar.
| Antibiotic | Ceftolozane/tazobactam, n (%) | ||||||
|---|---|---|---|---|---|---|---|
| MIC | < 0.25 | < 0.5 | < 0.75 | < 4 | > 256 | Total | |
| Ceftazidime/avibactam | < 0.1 | 13 (11.9) | 6 (5.5) | 1 (0.9) | 1 (0.9) | 0.0 | 21 (19.3) |
| < 0.25 | 7 (6.4) | 13 (11.9) | 0.0 | 0.0 | 0.0 | 20 (18.3) | |
| < 0.5 | 5 (4.6) | 37 (33.9) | 14 (12.8) | 7 (6.4) | 0.0 | 63 (57.8) | |
| < 0.75 | 0.0 | 0.0 | 0.0 | 3 (2.8) | 0.0 | 3 (2.8) | |
| < 1 | 0.0 | 1 (0.9) | 0.0 | 0.0 | 0.0 | 1 (0.9) | |
| > 256 | 0.0 | 0.0 | 0.0 | 0.0 | 1 (0.9) | 1 (0.9) | |
| Total | 25 (22.9) | 57 (52.3) | 15 (13.8) | 11 (10.1) | 1 (0.9) | 109 (100) | |